This Plain Language Summary of Publication from Future Oncology describes the results from a study looking at whether combining a second treatment (palbociclib) with an aromatase inhibitor helped people with HR+ breast cancer live longer.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer’ and was published in npj breast cancer. Read the original article here.